11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Advances in computational algorithms and tools have made the prediction of cancer patient outcomes using computational pathology feasible. However, predicting clinical outcomes from pre-treatment histopathologic images remains a challenging task, limited by the poor understanding of tumor immune micro-environments. In this study, an automatic, accurate, comprehensive, interpretable, and reproducible whole slide image (WSI) feature extraction pipeline known as, IMage-based Pathological REgistration and Segmentation Statistics (IMPRESS), is described. We used both H&E and multiplex IHC (PD-L1, CD8+, and CD163+) images, investigated whether artificial intelligence (AI)-based algorithms using automatic feature extraction methods can predict neoadjuvant chemotherapy (NAC) outcomes in HER2-positive (HER2+) and triple-negative breast cancer (TNBC) patients. Features are derived from tumor immune micro-environment and clinical data and used to train machine learning models to accurately predict the response to NAC in breast cancer patients (HER2+ AUC = 0.8975; TNBC AUC = 0.7674). The results demonstrate that this method outperforms the results trained from features that were manually generated by pathologists. The developed image features and algorithms were further externally validated by independent cohorts, yielding encouraging results, especially for the HER2+ subtype.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

          Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which pathological complete response is best correlated with long-term outcome, and to assess whether an increase in frequency of pathological complete response between treatment groups predicts improved EFS and OS. We searched PubMed, Embase, and Medline for clinical trials of neoadjuvant treatment of breast cancer. To be eligible, studies had to meet three inclusion criteria: include at least 200 patients with primary breast cancer treated with preoperative chemotherapy followed by surgery; have available data for pathological complete response, EFS, and OS; and have a median follow-up of at least 3 years. We compared the three most commonly used definitions of pathological complete response--ypT0 ypN0, ypT0/is ypN0, and ypT0/is--for their association with EFS and OS in a responder analysis. We assessed the association between pathological complete response and EFS and OS in various subgroups. Finally, we did a trial-level analysis to assess whether pathological complete response could be used as a surrogate endpoint for EFS or OS. We obtained data from 12 identified international trials and 11 955 patients were included in our responder analysis. Eradication of tumour from both breast and lymph nodes (ypT0 ypN0 or ypT0/is ypN0) was better associated with improved EFS (ypT0 ypN0: hazard ratio [HR] 0·44, 95% CI 0·39-0·51; ypT0/is ypN0: 0·48, 0·43-0·54) and OS (0·36, 0·30-0·44; 0·36, 0·31-0·42) than was tumour eradication from the breast alone (ypT0/is; EFS: HR 0·60, 95% CI 0·55-0·66; OS 0·51, 0·45-0·58). We used the ypT0/is ypN0 definition for all subsequent analyses. The association between pathological complete response and long-term outcomes was strongest in patients with triple-negative breast cancer (EFS: HR 0·24, 95% CI 0·18-0·33; OS: 0·16, 0·11-0·25) and in those with HER2-positive, hormone-receptor-negative tumours who received trastuzumab (EFS: 0·15, 0·09-0·27; OS: 0·08, 0·03, 0·22). In the trial-level analysis, we recorded little association between increases in frequency of pathological complete response and EFS (R(2)=0·03, 95% CI 0·00-0·25) and OS (R(2)=0·24, 0·00-0·70). Patients who attain pathological complete response defined as ypT0 ypN0 or ypT0/is ypN0 have improved survival. The prognostic value is greatest in aggressive tumour subtypes. Our pooled analysis could not validate pathological complete response as a surrogate endpoint for improved EFS and OS. US Food and Drug Administration. Copyright © 2014 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge

            The Cancer Genome Atlas (TCGA) is a public funded project that aims to catalogue and discover major cancer-causing genomic alterations to create a comprehensive “atlas” of cancer genomic profiles. So far, TCGA researchers have analysed large cohorts of over 30 human tumours through large-scale genome sequencing and integrated multi-dimensional analyses. Studies of individual cancer types, as well as comprehensive pan-cancer analyses have extended current knowledge of tumorigenesis. A major goal of the project was to provide publicly available datasets to help improve diagnostic methods, treatment standards, and finally to prevent cancer. This review discusses the current status of TCGA Research Network structure, purpose, and achievements.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Regulation and Function of the PD-L1 Checkpoint

              Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by counteracting T cell-activating signals. Antibody-based PD-1-PD-L1 inhibitors can induce durable tumor remissions in patients with diverse advanced cancers, and thus expression of PD-L1 on tumor cells and other cells in the tumor microenviroment is of major clinical relevance. Here we review the roles of the PD-1-PD-L1 axis in cancer, focusing on recent findings on the mechanisms that regulate PD-L1 expression at the transcriptional, posttranscriptional, and protein level. We place this knowledge in the context of observations in the clinic and discuss how it may inform the design of more precise and effective cancer immune checkpoint therapies.
                Bookmark

                Author and article information

                Contributors
                kunhuang@iu.edu
                Zaibo.Li@osumc.edu
                Journal
                NPJ Precis Oncol
                NPJ Precis Oncol
                NPJ Precision Oncology
                Nature Publishing Group UK (London )
                2397-768X
                27 January 2023
                27 January 2023
                2023
                : 7
                : 14
                Affiliations
                [1 ]GRID grid.169077.e, ISNI 0000 0004 1937 2197, School of Electrical and Computer Engineering, , Purdue University, ; West Lafayette, IN 47907 USA
                [2 ]GRID grid.257413.6, ISNI 0000 0001 2287 3919, Department of Electrical and Computer Engineering, , Indiana University – Purdue University Indianapolis, ; Indianapolis, IN 46202 USA
                [3 ]GRID grid.257413.6, ISNI 0000 0001 2287 3919, Department of Medicine, , Indiana University School of Medicine, ; Indianapolis, IN 46202 USA
                [4 ]GRID grid.448342.d, ISNI 0000 0001 2287 2027, Regenstrief Institute, ; Indianapolis, IN 46202 USA
                [5 ]GRID grid.257413.6, ISNI 0000 0001 2287 3919, Department of Biostatistics and Health Data Science, , Indiana University School of Medicine, ; Indianapolis, IN 46202 USA
                [6 ]GRID grid.257413.6, ISNI 0000 0001 2287 3919, Department of Pathology, , Indiana University School of Medicine, ; Indianapolis, IN 46202 USA
                [7 ]GRID grid.412332.5, ISNI 0000 0001 1545 0811, Department of Pathology, , The Ohio State University Wexner Medical Center, ; Columbus, OH 43210 USA
                [8 ]Roche Tissue Diagnostics, 1910 E. Innovation Park Drive, Tucson, AZ 85755 USA
                [9 ]GRID grid.67105.35, ISNI 0000 0001 2164 3847, University Hospitals Cleveland Medical Center, Case Western Reserve University, ; 11100 Euclid Avenue, Cleveland, OH 44106 USA
                [10 ]GRID grid.411377.7, ISNI 0000 0001 0790 959X, Department of Computer Science, , Indiana University Bloomington, ; Bloomington, IN 47408 USA
                [11 ]GRID grid.257413.6, ISNI 0000 0001 2287 3919, Department of Medical and Molecular Genetics, , Indiana University School of Medicine, ; Indianapolis, IN 46202 USA
                Author information
                http://orcid.org/0000-0001-6982-8285
                http://orcid.org/0000-0002-4134-5377
                http://orcid.org/0000-0003-1325-1696
                Article
                352
                10.1038/s41698-023-00352-5
                9883475
                36707660
                3ee22a59-09a4-45b7-85dd-b5d89dba2a5a
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 2 October 2021
                : 16 January 2023
                Categories
                Article
                Custom metadata
                © The Author(s) 2023

                breast cancer,outcomes research,predictive markers
                breast cancer, outcomes research, predictive markers

                Comments

                Comment on this article